Holen Sie sich die Stockscreener-App
137.21
2.76%
-3.90
Handel nachbörslich:
137.61
0.40
+0.29%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$141.11
Offen:
$140.43
24-Stunden-Volumen:
15.51M
Relative Volume:
2.15
Marktkapitalisierung:
$170.34B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
20.23
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-5.37%
1M Leistung:
-9.37%
6M Leistung:
+20.26%
1J Leistung:
+29.60%
1-Tages-Spanne:
$136.49
$141.00
1-Wochen-Bereich:
$136.49
$146.71
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.21 | 170.34B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
906.70 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.37 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.07 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
183.60 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.18 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BCGM Wealth Management LLC Invests in Gilead Sciences - National Today
BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Here is what to know beyond why Gilead Sciences, Inc. (GILD) is a trending stock - MSN
Former Gilead Sciences GC To Earn Over $2.5M Severance - Law360
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors - TipRanks
Gilead could potentially end HIV. But will it be able to? - Pharma Voice
Groupama Asset Managment Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Confluence Investment Management LLC Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Anderson Hoagland & Co. Purchases New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
AIA Group Ltd Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
CIBC Bancorp USA Inc. Invests $24.42 Million in Gilead Sciences - National Today
Gilead Sciences, Inc. $GILD Shares Bought by Swiss Life Asset Management Ltd - MarketBeat
Investment Research Partners LLC Takes $928,000 Position in Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Bancorp USA Inc. Makes New $24.42 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Coldstream Capital Management Inc. Acquires 8,807 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
A Look At Gilead Sciences (GILD) Valuation As Recent Returns Send Mixed Signals - Yahoo Finance
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance Australia
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Ciara Is Bringing Back the Pop Culture PSA (Exclusive) - Cosmopolitan
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead Sciences initiates challenging study for aggressive breast cancer form - Traders Union
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Gilead Sciences Inc Stock (GILD) Moved Down by 3.37% on Mar 18: Facts Behind the Movement - TradingKey
Gilead Sciences Stock Performance vs. Business Health Analysis 2026News and Statistics - IndexBox
Is trending stock Gilead Sciences, Inc. (GILD) a buy now? - MSN
Danske Bank A S Takes $133.05 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Captrust Financial Advisors Has $211.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V. - MarketBeat
Gilead Sciences CFO Dickinson sells $432k in stock - Investing.com
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares - MarketBeat
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead (GILD) executive sells 3,000 shares in planned trade - Stock Titan
Gilead Sciences (NASDAQ:GILD) CFO Sells $432,690.00 in Stock - MarketBeat
Manta Cares and Gilead Sciences Announce Collaboration to Support Patients Navigating Metastatic Breast and Lung Cancer - Femtech Insider
Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines - Traders Union
Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer - PRWeb
Cantor Fitzgerald reiterates Gilead stock rating on Yeztugo sales - Investing.com
National Bank of Canada FI Has $161.14 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push - Yahoo Finance
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Fort Point Capital Partners LLC Sells 8,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bank of Nova Scotia Reduces Gilead Sciences Stake - National Today
CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):